Tìm theo
Phenylephrine
Các tên gọi khác (10 ) :
  • (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol
  • (-)-m-Hydroxy-α-(methylaminomethyl)benzyl alcohol
  • Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, (R)-
  • Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-
  • Benzyl alcohol, m-hydroxy-alpha-((methylamino)methyl)-, (-)-
  • Fenilefrina
  • l-(3-Hydroxyphenyl)-N-methylethanolamine
  • Phenylephrine
  • Phenylephrinum
  • R(-)-Phenylephrine
Thuốc tim mạch
Thuốc Gốc
Small Molecule
CAS: 59-42-7
ATC: C01CA06, R01AA04, R01AB01, R01BA03, S01FB01, S01GA05, C05AX03
ĐG : Accutome Inc. , http://www.accutome.com
CTHH: C9H13NO2
PTK: 167.205
Phenylephrine is a sympathomimetic amine that acts predominantly on α-adrenergic receptors. It is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
Phân tử khối
167.205
Monoisotopic mass
167.094628665
InChI
InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1
InChI Key
InChIKey=SONNWYBIRXJNDC-VIFPVBQESA-N
IUPAC Name
3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol
Traditional IUPAC Name
phenylephrine
SMILES
CNC[[email protected]](O)C1=CC(O)=CC=C1
Độ tan chảy
140-145 °C
Độ hòa tan
Freely soluble in water
logP
-0.31
logS
-0.88
pKa (strongest acidic)
9.07
pKa (Strongest Basic)
9.69
PSA
52.49 Å2
Refractivity
47.25 m3·mol-1
Polarizability
18.2 Å3
Rotatable Bond Count
3
H Bond Acceptor Count
3
H Bond Donor Count
3
Physiological Charge
1
Number of Rings
1
Bioavailability
1
Rule of Five
true
Ghose Filter
true
pKa
8.97
Dược Lực Học : Phenylephrine is a powerful vasoconstrictor. It is used as a nasal decongestant and cardiotonic agent. Phenylephrine is a postsynaptic α1-receptor agonist with little effect on β-receptors of the heart. Parenteral administration of phenylephrine causes a rise in systolic and diastolic pressures, a slight decrease in cardiac output, and a considerable increase in peripheral resistance; most vascular beds are constricted, and renal, splanchnic, cutaneous, and limb blood flows are reduced while coronary blood flow is increased. Phenelephrine also causes pulmonary vessel constriction and subsequent increase in pulmonary arterial pressure. Vasoconstriction in the mucosa of the respiratory tract leads to decreased edema and increased drainage of sinus cavities.
Cơ Chế Tác Dụng : Phenylephrine is a sympathomimetic amine that acts predominantly on α-adrenergic receptors. It is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs. In general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α1A (chromosome 8), α1B (chromosome 5), and α1D (chromosome 20). Phenylephrine appears to act similarly on all three receptor subtypes. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of the α1-receptor activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Phenylephrine produces its local and systemic actions by acting on α1-adrenergic receptors peripheral vascular smooth muscle. Stimulation of the α1-adrenergic receptors results in contraction arteriolar smooth muscle in the periphery. Phenylephrine decreases nasal congestion by acting on α1-adrenergic receptors in the arterioles of the nasal mucosa to produce constriction; this leads to decreased edema and increased drainage of the sinus cavities.
Dược Động Học :
▧ Absorption :
Completely absorbed after oral administration. It has a reduced bioavailability (compared to pseudoephedrine) following oral administration due to significant first-pass metabolism in the intestinal wall. Compared to IV administration, bioavailability is approximately 38%. Peak serum concentrations are achieved approximately 0.75-2 hours following oral administration. Phenylephrine should be administered parenterally to achieve cardiovascular effects. Occasionally, systemic effects are observed following oral inhalation.
▧ Protein binding :
95% binding-plasma proteins
▧ Metabolism :
Undergoes extensive first-pass metabolism in the intestinal wall and extensive metabolism in the liver. Sulfate conjugation, primarily in the intestinal wall, and oxidative metabolism by monoamine oxidase (MAO) represent the principle routes of metabolism. Glucuronidation occurs to a lesser extent. Phenylephrine and its metabolites are mainly excreted in urine/ .
▧ Half Life :
2.1 to 3.4 hours
Chỉ Định : Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.
Tương Tác Thuốc :
  • Alseroxylon Increased arterial pressure
  • Amitriptyline The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of phenylephrine.
  • Amoxapine The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of phenylephrine.
  • Clomipramine The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of phenylephrine.
  • Deserpidine Increased arterial pressure
  • Desipramine The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of phenylephrine.
  • Doxepin The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of phenylephrine.
  • Ergonovine Possible marked increase of arterial pressure
  • Guanethidine Phenylephrine may decrease the effect of guanethidine.
  • Hyaluronidase Avoid combination because hyaluronidase can potentiate the vasoconstrictive effect of phenylephrine.
  • Imipramine The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of phenylephrine.
  • Iobenguane Sympathomimetic that increase chances of producing a false negative imaging result
  • Isocarboxazid Increased arterial pressure
  • Linezolid Possible increase of arterial pressure
  • Methyldopa Increased arterial pressure
  • Methylergometrine Possible marked increase of arterial pressure
  • Midodrine Increased arterial pressure
  • Moclobemide Moclobemide increases the sympathomimetic effect of phenylephrine.
  • Nortriptyline The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of phenylephrine.
  • Oxytocin Possible marked increase of arterial pressure
  • Pargyline Increased arterial pressure
  • Phenelzine Increased arterial pressure
  • Protriptyline The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of phenylephrine.
  • Rasagiline Increased arterial pressure
  • Reserpine Increased arterial pressure
  • Tranylcypromine The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Phenylephrine. Concomitant therapy should be avoided.
  • Trimipramine Trimipramine may increase the vasopressor effect of the alpha1-agonist, Phenylephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.
Liều Lượng & Cách Dùng : Cream - Topical - 0.25%
Injection, solution - Intramuscular - 10 mg/ml
Injection, solution - Intravenous - 10 mg/ml
Liquid - Ophthalmic
Ointment - Topical - 0.25%
Strip - Oral - 2.5 mg
Suppository - Rectal - 0.25%
Tablet - Oral - 10 mg
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : AK-Dilate
  • Công ty :
    Sản phẩm biệt dược : AK-Nefrin
  • Công ty :
    Sản phẩm biệt dược : Alconefrin
  • Công ty :
    Sản phẩm biệt dược : Dionephrine
  • Công ty :
    Sản phẩm biệt dược : Mesatone
  • Công ty :
    Sản phẩm biệt dược : Minims Phenylephrine
  • Sản phẩm biệt dược : Mydfrin
  • Công ty : Bayer
    Sản phẩm biệt dược : Neo-Synephrine
  • Công ty :
    Sản phẩm biệt dược : Neofrin
  • Công ty :
    Sản phẩm biệt dược : Ocugestrin
  • Công ty :
    Sản phẩm biệt dược : Phenoptic
  • Công ty :
    Sản phẩm biệt dược : Prefrin
  • Công ty :
    Sản phẩm biệt dược : Rhinall
  • Công ty :
    Sản phẩm biệt dược : Spersaphrine
  • Công ty :
    Sản phẩm biệt dược : Visadron
Đóng gói
... loading
... loading